Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2011 Mar;96(3):349-52.
doi: 10.3324/haematol.2010.030023.

Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Mario Cazzola
Editorial

Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

Mario Cazzola. Haematologica. 2011 Mar.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier survival curves of 943 patients diagnosed with MDS according to the 2008 WHO criteria at the Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo & University of Pavia, Pavia, Italy. (A) Patients grouped according to the FAB classification (patients with 5–19% bone marrow blasts and Auer rods were classified as RAEB-t). (B) Patients grouped according to the WHO classification. Patients classified as RA or RARS according to the FAB classification (panel A) are split here (panel B) into two subgroups with different survival based on the presence of unilineage [RCUD or RARS, including also MDS with del(5q)] or multi-lineage dysplasia (RCMD). Moreover, patients with RAEB (panel A) are also split here into two subgroups according to their blast percentage (5–9% in RAEB-1, 10–19% in RAEB-2).
Figure 2.
Figure 2.
Survival of 644 MDS patients diagnosed according to the WHO criteria at the Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo & University of Pavia, Pavia, Italy, and stratified according to the WPSS. (A) Kaplan-Meier curves. (B) Kaplan-Meier time-dependent curves of MDS patients grouped according to the dynamic WPSS.
See this image and copyright information in PMC

Comment in

References

    1. Cazzola M, Malcovati L. Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6):536–8. - PubMed
    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
    1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189–99. - PubMed
    1. Reiter A, Invernizzi R, Cross NC, Cazzola M. Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2009;94(12):1634–8. - PMC - PubMed
    1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–302. - PubMed

Publication types

MeSH terms

Substances